Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02237677 · ClinicalTrials.gov registry record
CB1 Receptor PET Imaging Reveals Gender Differences in PTSD
A clinical trial, sponsored by NYU Langone Health.
- Terminated
- Registry status
- 36
- Enrollment target
NCT02237677: Clinical Trial study, sponsored by NYU Langone Health.
NCT02237677 is a clinical trial that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02237677 was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- 36 participants
- Enrollment target
Study Summary
The objective of the proposed translational study is to test a model, based upon basic science studies, exploring multisystem impairments in PTSD including endocannabinoid (eCB) and glucocorticoids in the modulation of fear memories by examining the cannabinoid type 1 (CB1) receptor in a PTSD fear circuit as well as glucocorticoid function. The investigators propose that impaired eCB signaling in PTSD resulting in the maladaptive neurobehavioral response to the stressor is associated with an upregulation of the CB1 receptors and insufficient glucocorticoid signaling.
Primary Outcome
To examine group differences in cerebral CB1 receptor expression in PTSD and controls within a fear circuit of cortical and subcortical brain regions that regulate stress-related behaviors using the CB1 radioligand \[11C\]OMAR and PET. Hypothesis: PTSD patients will show greater \[11C\]OMAR VT (i.e. CB1 binding) values than both control groups, trauma-exposed and non-trauma exposed control subjects who will not be different.
Interventions
- OTHER Positron emission tomography (PET) imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-03 |
Why NCT02237677 stopped before completion
NCT02237677 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Positron emission tomography (PET) imaging is the first listed.
NCT02237677 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02237677 about?
NCT02237677 is a clinical study titled "CB1 Receptor PET Imaging Reveals Gender Differences in PTSD". The objective of the proposed translational study is to test a model, based upon basic science studies, exploring multisystem impairments in PTSD including endocannabinoid (eCB) and glucocorticoids in the modulation of fear memories by examining the cannabinoid type 1 (CB1) receptor in a PTSD fear c...
What is the current status of trial NCT02237677?
This trial is currently terminated. The enrollment target is 36 participants. The study started on 2012-06. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02237677?
The interventions under investigation include: Positron emission tomography (PET) imaging (OTHER).
Who is sponsoring clinical trial NCT02237677?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia